Jason Lettmann
Jason Lettmann joined Promedior’s board in 2014 and is the Company’s CEO. Jason is a General Partner of Lightstone Ventures as well as a General Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. In addition to his role at Promedior, Jason serves on the Board of Directors of ALX Therapeutics Ltd., Carrick Therapeutics Ltd., Cerevance Inc, FIRE1 Ltd., Relievant Medsystems Inc., and Second Genome Inc.. Jason was previously a Director and led investments in Ra Pharmaceuticals (NASDAQ: RARX) and Vapotherm (NYSE: VAPO) as well as actively involved with Morgenthaler’s investments in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), and Transcend Medical (acquired by Alcon). Jason established Lightstone’s Europe office in 2014 located in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.

Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. At Split Rock, Jason was actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical (NASDAQ: ENTL), and Evalve (acquired by Abbott) and a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013. Jason’s experience also includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and payer sectors. Jason also worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics.

Jason has an M.B.A. with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.
Richard Jack, Ph.D.
Chief Operating Officer and Chief Scientific Officer
Rick joined Promedior in 2014 as Chief Scientific Officer and Chief Operating Officer in 2015. He has more than 20 years of drug discovery research and development experience in the biotechnology and pharmaceutical industry concentrating on innate immunity and immunological and inflammatory diseases. Prior to joining Promedior, he was Vice President of Research for Tanabe Research Labs-USA (TRL), the US discovery arm of Mitsubishi-Tanabe Pharma. While there, he and his team advanced multiple small molecule programs into development. Prior to his tenure with TRL, Rick was a scientific co-founder and Vice President, Biology at Triad Therapeutics, a structure-based drug discovery company that developed a leading kinase inhibitor program that was licensed to Novartis and continues in clinical development. He began his biopharmaceutical career at La Jolla Pharmaceutical, where he developed and advanced preclinical and clinical biologics programs for antibody-mediated diseases.

Prior to joining the biopharmaceutical industry, Rick spent more than 10 years in the Department of Rheumatology/Immunology at Brigham and Women's Hospital/Harvard Medical School where he was also an NIH-funded faculty member of the graduate programs for both Immunology and Cell and Molecular Biology. His lab focused on mechanisms of autoimmune and inflammatory disease, particularly in the areas of the complement system and leukocyte activation. Rick is an author of 50 scientific papers and four patents. He received an AB in Biology from Bates College and a PhD in Immunology from the University of Connecticut Health Center, and he performed his postdoctoral fellowship in Immunoparasitology at ILRAD in Nairobi, Kenya.
Renu Gupta, MD
Chief Medical Officer
Renu, who has more than 25 years of development, regulatory and senior management experience in the biopharmaceutical industry, has been Promedior’s Chief Medical Officer since January 2016. She previously served as Chief Medical Officer at Insmed. Prior to that, she served as the Executive Vice President of Development and Chief Medical Officer of Transave. Renu also served as Senior Vice President of Development at Antigenics, Inc. and as Vice President and Head of US Clinical Research and Development and Global Head of Cardiovascular, Metabolics, Endocrine and Gastroenterology Research at Novartis.

Renu started her pharma career at Bristol-Myers Squibb, where she was responsible for clinical research, business development and global development and marketing strategy for infectious diseases and immunology. She received her bachelor and medical degrees from the University of Zambia and completed her medical and post-doctoral training at the Albert Einstein Medical Center, the Wistar Institute of Anatomy and Biology, Children’s Hospital of Philadelphia, and the University of Pennsylvania, where she was Adjunct Assistant Professor. Her work has been published in leading peer-reviewed journals and she has been active in numerous relevant academic and professional societies.

Renu is a founding member of the Industrial Management Board at Harvard Medical School. She served as Chair of the Medical Advisory Council for Antigenics, is a past member of the Scientific Advisory Board at Cerimon Pharmaceuticals and the Institute of Medicine Forum on Emerging Infections, and is a board member of Aim at Melanoma, formerly Charlie Guild Melanoma Foundation, Transave Inhalation and Breath Therapeutics.
W. Scott Willett, Ph.D.
Vice President, Biopharmaceutical Development
Scott has more than 30 years of experience in the biopharmaceutical industry developing and manufacturing recombinant protein human therapeutics. For the last 12 years at Promedior, Scott has led the development of the company’s lead clinical-stage antifibrotic, PRM-151, from research through Phase 2 clinical manufacturing. Prior to Promedior, he served as Director of Process Development at Neose Technologies, leading development and technology transfer for clinical-phase glycoengineered protein therapeutics. Before joining Neose, he was a Process Development Scientist at Amgen, Thousand Oaks, where he led teams in development of Phase 1 cGMP purification processes for several proteins, in addition to supporting Amgen’s commercial products. Scott holds a PhD in Pharmaceutical Chemistry from the University of California at San Francisco and a BS degree in Chemical Engineering from the University of Michigan at Ann Arbor.
Kieran McCarthy
Vice President, Business Development
Kieran joined Promedior in December 2018 as Vice President of Business Development and is responsible for Promedior’s business development activities. Kieran has more than 17 years of experience in the biopharmaceutical industry in both in-licensing and out-licensing. Prior to joining Promedior Kieran worked at FibroGen where he was responsible for partnering activities for both FibroGen’s fibrosis program, pamrevlumab, and its biomaterials business including both in-licensing and out-licensing activities. Kieran’s responsibilities included managing all due diligence activities, leading negotiations and also serving as the lead for general business and commercial activities related to both business lines. Prior to joining FibroGen, Kieran worked at the Ortho Biotech division of Johnson & Johnson where he was part of a team assessing in-licensing opportunities across several therapeutic areas including, oncology, immunology, nephrology and virology. Transactions completed at Johnson & Johnson included the in-licensing of Teleprevir, Velcade, and Yondelis. Kieran also worked on the post- acquisition integration of Tibotec-Virco N.V. Kieran received an MBA from Columbia University and a B.S. in Commerce from the University of Virginia.
Bernt van den Blink, MD, PhD
Senior Medical Director
Bernt joined Promedior in March 2016 as Medical Director. He serves as the company’s global medical lead for the on-going clinical development of PRM-151 in Idiopathic Pulmonary Fibrosis (IPF) and Myelofibrosis. Prior to joining Promedior, Bernt was a faculty member in the Department of Pulmonary Medicine at the Erasmus University Medical Center (Rotterdam, The Netherlands) for eight years. Board-certified in Pulmonology, Bernt has expertise in rare lung diseases, including interstitial lung diseases and lung transplantation. At Erasmus, he led the Inflammation and Remodeling research group focusing on translational work in interstitial lung diseases, including IPF. In addition to conducting preclinical research, he was an active clinical trial investigator.

Bernt obtained both his MD and PhD (Immunology) degrees at the University of Amsterdam, where he was also a Fellow in Internal Medicine and Pulmonology. He is the author of more than 40 peer-reviewed articles and an active member in several international lung societies.

At Promedior, we are focused on developing novel therapeutics to address the unmet needs of patients with fibrosis.